Patent US4758428A successfully refreshed from Google Patents.
US4758428A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Multiclass hybrid interferons
Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1985-07-15
•
Granted: 1988-07-19
•
Expires: 2005-07-15
Abstract
Abstract New multiclass hybrid interferon polypeptides, their corresponding encoding recombinant DNA molecules and transformed hosts which produce the new interferons are described. The amino acid sequences of these hybrids include at least two different subsequences, one of which has substantial homology with a portion of a first class of interferon (e.g., HuIFN-α) and the other which has substantial homology with a portion of a second class of interferon (e.g., HuIFN-β). Data indicates the interferon activity of α-β hybrids may be substantially restricted to either cell growth regulatory activity or antiviral activity.
Inventors
- 👤 David F. Mark
- 👤 Abla A. Creasey
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-26 13:23
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/52; C07K14/555; C07K14/565; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S435/00; Y10S435/811; Y10S930/00; Y10S930/01; Y10S930/14; Y10S930/142
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
53 words
A multiclass hybrid interferon polypeptide having an amino acid sequence composed of two distinct amino acid subsequences one of which subsequences comprises the amino acid sequence 1-73 of the amino terminal enc of HuIFN-α1, and the other of which subsequences comprises the amino acid sequence 74-166 of the carboxy terminal end of HuIFN-β1.
Claim 2
Dependent Claim
53 words
A multiclass hybrid interferon polypeptide having an amino acid sequence composed of two distinct amino acid subsequences one of which subsequences comprises the amino acid sequence 1-73 of the amino terminal enc of HuIFN-α1, and the other of which subsequences comprises the amino acid sequence 74-166 of the carboxy terminal end of HuIFN-β1.
Claim 3
Dependent Claim
53 words
A multiclass hybrid interferon polypeptide having an amino acid sequence composed of two distinct amino acid subsequences one of which subsequences comprises the amino acid sequence 1-41 of the amino terminal enc of HuIFN-α61A, and the other of which subsequences comprises the amino acid sequence 47-166 of the carboxy terminal end of HuIFN-β1.
Claim 4
Dependent Claim
53 words
A multiclass hybrid interferon polypeptide having an amino acid sequence composed of two distinct amino acid subsequences one of which subsequences comprises the amino acid sequence 1-41 of the amino terminal enc of HuIFN-α61A, and the other of which subsequences comprises the amino acid sequence 47-166 of the carboxy terminal end of HuIFN-β1.
Claim 5
Dependent Claim
53 words
A multiclass hybrid interferon polypeptide having an amino acid sequence composed of two distinct amino acid subsequences one of which subsequences comprises the amino acid sequence 1-73 of the amino terminal eno of HuIFN-β1, and the other of which subsequences comprises the amino acid sequence 74-167 of the carboxy terminal end of HuIFN-α1.
Claim 6
Dependent Claim
53 words
A multiclass hybrid interferon polypeptide having an amino acid sequence composed of two distinct amino acid subsequences one of which subsequences comprises the amino acid sequence 1-73 of the amino terminal eno of HuIFN-β1, and the other of which subsequences comprises the amino acid sequence 74-167 of the carboxy terminal end of HuIFN-α1.
Claim 7
Dependent Claim
30 words
A pharmaceutical composition comprising a cell growth regulating or viral inhibiting effective amount of the multiclass hybrid interferon polypeptide of claim 1 admixed with a pharmaceutically acceptable vehicle or carrier.
Claim 8
Dependent Claim
30 words
A pharmaceutical composition comprising a cell growth regulating or viral inhibiting effective amount of the multiclass hybrid interferon polypeptide of claim 2 admixed with a pharmaceutically acceptable vehicle or carrier.
Claim 9
Dependent Claim
30 words
A pharmaceutical composition comprising a cell growth regulating or viral inhibiting effective amount of the multiclass hybrid interferon polypeptide of claim 3 admixed with a pharmaceutically acceptable vehicle or carrier.
Claim 10
Dependent Claim
29 words
A method of regulating cell growth in an animal patient comprising administering to said patient a cell growth regulating amount of the multiclass hybrid interferon polypeptide of claim 1.
Claim 11
Dependent Claim
32 words
A method of regulating cell growth in a human or other animal patient comprising administering to said patient a cell growth regulating amount of the multiclass hybrid interferon polypeptide of claim 3.
Claim 12
Dependent Claim
30 words
A method of treating an animal patient for a viral disease comprising administering to the patient a viral disease inhibiting amount of the multiclass hybrid interferon polypeptide of claim 2.
References Cited (Backward Citations)
US4678751A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1991-07-19 | 1992-01-18 | 1992-07-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1995-07-19 | 1996-01-18 | 1996-07-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1999-07-19 | 2000-01-18 | 2000-07-19 | $7700.00 | Window Closed / Lapsed |